Will a Blood Test Make It Possible to Diagnose Cancer 4 Years in Advance?

Cancer treatment in advanced stages is still not as successful as hoped. Detecting cancer at an early stage therefore remains the most fundamental strategy for improving the outcomes of this disease. When early diagnosis is possible, survival rates increase through surgical removal of the tumor from the body or treatment with medication. Research shows that the 5-year survival rate is 91% for patients whose cancer is diagnosed early, whereas when it is diagnosed at an advanced stage, the overall 5-year survival rate falls to as low as 26%. These results show that diagnosing cancer as early as possible is extremely important.
At present, a limited number of screening tests are available for a few types of cancer, including colonoscopy, prostate-specific antigen, mammography, and cervical cytology (see all cancer screening tests). However, there are questions about the effectiveness of some tests. Many types of cancer lack effective noninvasive early screening options (methods that do not disrupt the integrity of the body).
Liquid / Blood Biopsy and Its Importance in Cancer Diagnosis
Recently, circulating tumor DNA (ctDNA) has become a promising cancer biomarker. Liquid biopsy, the detection of ctDNA through a blood test, has been found to be a noninvasive method of detecting cancer and useful for identifying personalized treatments in advanced cancers and detecting any cancer remaining in the body after treatment. However, many diagnostic tests in use focus on detecting cancer in patients who have already been diagnosed. A small number of studies have also managed to detect the presence of cancer before diagnosis in a limited number of cancer types. Alongside the advantages ctDNA offers in early diagnosis, certain limitations make it difficult to use. In particular, the small amount of cancer DNA in plasma in early-stage cancers reduces the effectiveness of the method. Typical tests used for ctDNA mutation screening can be prone to errors, reducing the reliability of the test. At the same time, the evolutionary nature of tumor cells results in a very large number of mutations, increasing the number that must be screened to reach a result and making the task more difficult.
A Study Offering Hope for Early Cancer Diagnosis
All these shortcomings lead scientists to investigate a diagnostic method that can identify cancer as accurately and as early as possible, before it spreads to different sites, and help obtain the best response to treatment. Nature Communications published a study on 21 July that offered great hope by allowing cancer to be diagnosed with a blood test before any symptoms appear.
Kun Zhang, who took part in the study, summarizes the importance of the findings as follows: “In our study, we managed to diagnose cancer approximately 4 years in advance by collecting and analyzing blood samples from individuals. This had not been done before”. Efforts to develop blood tests for cancer typically involved collecting blood samples from people diagnosed with the disease. The next step generally involved analyzing genetic mutations, DNA methylation ( epigenetic changes occurring in DNA), or certain blood proteins to determine whether cancer cells could be accurately detected in the collected blood samples.
In contrast to this previous approach, Zhang and colleagues began collecting blood samples from people before they received any cancer diagnosis in the new study. In the study, which began in 2007, samples were collected from more than 123 thousand healthy individuals, and cancer was detected in approximately 1,000 people over the following 10 years. The researchers focused on developing tests for some of the most commonly observed cancers, including stomach, esophageal (food pipe), colorectal (large bowel), lung, and liver cancer. PanSeer is the name of the test developed to detect the addition of an epigenetic group to DNA (DNA methylation), which changes genetic activity. This detection method was chosen because many previous studies had shown that abnormal DNA methylation could indicate various cancers, including pancreatic and colon cancer.
How the PanSeer Test Works
The basic principle of this test is to isolate DNA from a blood sample and measure DNA methylation in 500 gene regions most likely to indicate the presence of cancer. This algorithm-based method produces a single score indicating the person's likelihood of having cancer. The researchers tested blood samples from 191 participants who developed cancer and the same number of healthy individuals. In the study, the test achieved approximately 90% accuracy and a 5% false-positive rate, detecting cancer 4 years before symptoms appeared.
Scientists not involved in the research described it as an important study and stated that, for the PanSeer test to be used clinically, it must be tested independently by different researchers, and if similar results are obtained, its introduction into clinical practice could bring important advances in cancer diagnosis and treatment. Despite its important advantages, the test carries a risk of false-positive results. Prof. Usha Menon stated that it would be better to initially use it in high-risk individuals and emphasized that physicians need to design a second panel of tests to identify a specific cancer type and rule out false positives. Zhang agrees that further studies are needed and notes that the test could make a major difference in cancers with very high mortality rates, with studies on pancreatic cancer in particular continuing. Molecular pathologist Colin Pritchard commented on the study as follows: “Even when these blood tests become available, they will probably not detect all cancers before symptoms develop. Each cancer has different growth characteristics. Very rapidly growing cancers may not be detected at an early stage even with annual screening. Some types of cancer, meanwhile, cannot be detected with a blood test because they do not produce a measurable signal in blood plasma. Although there is currently no accurate blood-based screening test, research in this area continues rapidly. This is not an impossible undertaking.”
Conclusion & Commentary
The results of this study are extremely exciting. Early diagnosis is particularly important for cancers with high mortality rates. As the findings suggest, detecting cancer as far as several years in advance will certainly improve a person's quality of life when an appropriate treatment plan is followed. What must not be forgotten here is the 5% rate of false-positive results. A certain rate of false positives is acceptable in conventional cancer screening methods. However, before cancer is visible radiologically, "mistakenly" telling someone through a liquid biopsy that they are highly likely to develop cancer in the future would create medical, legal, and ethical problems. Both confirmatory studies and a legal framework are needed before liquid biopsies can be used routinely for early cancer diagnosis.
*
Sources
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.
Nature Communications, 21 Kuly 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.